Business Context and Reporting Period
This Form 8-K was filed by pSivida Corp. on March 5, 2012. The report discloses a corporate governance event regarding the Board of Directors. Note: The request metadata lists "Eyepoint, Inc.", but the filing text explicitly identifies the registrant as "pSivida Corp."
Key Event: Election of Director
On March 5, 2012, the Board of Directors elected Douglas Godshall as a Director. Mr. Godshall has served as the Chief Executive Officer of HeartWare International, Inc. since September 2006.
Compensatory Arrangements
- Equity Grant: Mr. Godshall received an initial grant of an option to purchase 60,000 shares of pSivida common stock.
- Exercise Price: $2.10 per share.
- Vesting Schedule: The options vest in three equal portions on the first, second, and third anniversaries of the grant date.
- Expiration: The options remain exercisable until the tenth anniversary of the grant date.
- Conditions: The grant is subject to shareholder approval and aligns with the company's non-executive director compensatory arrangements detailed in the Definitive Proxy Statement filed on October 25, 2011.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on the appointment of a director and associated compensation.
Material Changes
The material change reported is the addition of Douglas Godshall to the Board of Directors and the issuance of the associated stock option grant.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, or specific risk factors beyond the standard requirement for shareholder approval of the equity grant.
Investor Verification Checklist
- Verify the shareholder approval status of the 60,000 share option grant to Douglas Godshall.
- Review the Definitive Proxy Statement filed on October 25, 2011, for full details on non-executive director compensation policies.
- Confirm the current share price relative to the $2.10 exercise price to assess the intrinsic value of the grant.
- Clarify the discrepancy between the request metadata ("Eyepoint, Inc.") and the filing registrant ("pSivida Corp.").